
Feb 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O/SANOFI SASY.PA
DUPIXENT® (DUPILUMAB) SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TARGETED TREATMENT OF BULLOUS PEMPHIGOID (BP)
DUPIXENT® (DUPILUMAB) SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TARGETED TREATMENT OF BULLOUS PEMPHIGOID (BP)
DUPIXENT® (DUPILUMAB) SBLA ACCEPTED FOR FDA PRIORITY REVIEW FOR TARGETED TREATMENT OF BULLOUS PEMPHIGOID (BP)
FDA DECISION ON THIS ON DUPIXENT EXPECTED BY JUNE 20, 2025
Source text: ID:nGNXf53dj
Further company coverage: REGN.O